Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  
The good —FDA approves BMS schizophrenia drug 
The bad — bluebird bio announces layoffs 
The ugly —J&amp;J talc subsidiary files for bankruptcy

Gilead inks deal with generics manufacturers to expand HIV drug access, J&J announces layoffs, Amgen sued for hiding $10.7B tax bill  [The good, the bad, the ugly]

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more